IN2015DN03219A - - Google Patents
Info
- Publication number
- IN2015DN03219A IN2015DN03219A IN3219DEN2015A IN2015DN03219A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A IN 3219DEN2015 A IN3219DEN2015 A IN 3219DEN2015A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A
- Authority
- IN
- India
- Prior art keywords
- pridopidine
- laquinimod
- treating
- neurodegenerative disorder
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261706695P | 2012-09-27 | 2012-09-27 | |
| US201361879004P | 2013-09-17 | 2013-09-17 | |
| PCT/US2013/062482 WO2014052933A1 (en) | 2012-09-27 | 2013-09-27 | Laquinimod and pridopidine for treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03219A true IN2015DN03219A (es) | 2015-10-02 |
Family
ID=50339469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3219DEN2015 IN2015DN03219A (es) | 2012-09-27 | 2013-09-27 |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US20150209346A1 (es) |
| EP (1) | EP2900330A4 (es) |
| CN (1) | CN104902958A (es) |
| AU (1) | AU2013323131A1 (es) |
| BR (1) | BR112015006623A2 (es) |
| CA (1) | CA2884781A1 (es) |
| EA (1) | EA201590655A8 (es) |
| HK (2) | HK1211525A1 (es) |
| IL (1) | IL237742A0 (es) |
| IN (1) | IN2015DN03219A (es) |
| MX (1) | MX2015003608A (es) |
| WO (1) | WO2014052933A1 (es) |
| ZA (1) | ZA201502600B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| MX2009011020A (es) * | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| AU2012306386B2 (en) | 2011-09-07 | 2017-06-15 | Teva Pharmaceuticals International Gmbh | Polymorphic form of pridopidine hydrochloride |
| UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CN105592848A (zh) | 2013-06-21 | 2016-05-18 | 梯瓦制药国际有限责任公司 | 高剂量普利多匹定用于治疗亨廷顿舞蹈症的用途 |
| EP3082814A4 (en) * | 2013-12-20 | 2017-06-21 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay huntington's disease progression |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| CA2961187A1 (en) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceuticals Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| EP3324967A4 (en) * | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| EP3504187A4 (en) | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE |
| US11253594B2 (en) | 2017-07-07 | 2022-02-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Drug combinations for protecting against neuronal cell death |
| FI3668509T3 (fi) | 2017-08-14 | 2023-03-14 | Prilenia Neurotherapeutics Ltd | Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla |
| AU2020293739B2 (en) * | 2019-06-12 | 2023-11-30 | Prilenia Neurotherapeutics Ltd. | Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2170327B1 (en) * | 2007-06-18 | 2014-10-22 | A.Carlsson Research AB | Use of dopamine stabilizers |
| NZ593090A (en) * | 2008-11-13 | 2013-06-28 | Link Medicine Corp | Azaquinolinone derivatives and uses thereof |
| ME02495B (me) * | 2009-08-10 | 2017-02-20 | Teva Pharma | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| JP2013544887A (ja) * | 2010-12-07 | 2013-12-19 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用 |
-
2013
- 2013-09-27 AU AU2013323131A patent/AU2013323131A1/en not_active Abandoned
- 2013-09-27 US US14/426,327 patent/US20150209346A1/en not_active Abandoned
- 2013-09-27 CA CA2884781A patent/CA2884781A1/en active Pending
- 2013-09-27 WO PCT/US2013/062482 patent/WO2014052933A1/en active Application Filing
- 2013-09-27 EP EP13840841.4A patent/EP2900330A4/en not_active Withdrawn
- 2013-09-27 MX MX2015003608A patent/MX2015003608A/es unknown
- 2013-09-27 EA EA201590655A patent/EA201590655A8/ru unknown
- 2013-09-27 IN IN3219DEN2015 patent/IN2015DN03219A/en unknown
- 2013-09-27 BR BR112015006623A patent/BR112015006623A2/pt active Search and Examination
- 2013-09-27 CN CN201380050913.8A patent/CN104902958A/zh active Pending
- 2013-09-27 US US14/040,586 patent/US20140088140A1/en not_active Abandoned
-
2015
- 2015-03-15 IL IL237742A patent/IL237742A0/en unknown
- 2015-04-17 ZA ZA2015/02600A patent/ZA201502600B/en unknown
- 2015-12-15 HK HK15112317.4A patent/HK1211525A1/xx unknown
-
2016
- 2016-03-01 HK HK16102362.8A patent/HK1214553A1/zh unknown
-
2017
- 2017-07-20 US US15/655,580 patent/US20170319569A1/en not_active Abandoned
- 2017-11-02 US US15/801,703 patent/US20180133209A1/en not_active Abandoned
-
2018
- 2018-05-08 US US15/974,112 patent/US20180250285A1/en not_active Abandoned
- 2018-08-30 US US16/117,604 patent/US20180369228A1/en not_active Abandoned
- 2018-12-18 US US16/223,993 patent/US20190117639A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013323131A1 (en) | 2015-05-07 |
| ZA201502600B (en) | 2016-06-29 |
| EA201590655A8 (ru) | 2016-07-29 |
| US20180369228A1 (en) | 2018-12-27 |
| US20180133209A1 (en) | 2018-05-17 |
| EP2900330A1 (en) | 2015-08-05 |
| US20150209346A1 (en) | 2015-07-30 |
| HK1214553A1 (zh) | 2016-07-29 |
| CA2884781A1 (en) | 2014-04-03 |
| CN104902958A (zh) | 2015-09-09 |
| US20180250285A1 (en) | 2018-09-06 |
| US20170319569A1 (en) | 2017-11-09 |
| US20140088140A1 (en) | 2014-03-27 |
| US20190117639A1 (en) | 2019-04-25 |
| IL237742A0 (en) | 2015-05-31 |
| EP2900330A4 (en) | 2016-05-25 |
| WO2014052933A1 (en) | 2014-04-03 |
| HK1211525A1 (en) | 2016-05-27 |
| MX2015003608A (es) | 2015-06-05 |
| EA201590655A1 (ru) | 2015-12-30 |
| BR112015006623A2 (pt) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03219A (es) | ||
| WO2014052935A3 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| MX2015006234A (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
| PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
| MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| MX2021005317A (es) | Composiciones y métodos para absorción transmucosa. | |
| PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| BR112012022552A2 (pt) | uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas | |
| MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| MX358512B (es) | Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva. | |
| MX370451B (es) | Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular. | |
| IN2013MU01155A (es) | ||
| IN2013MU01252A (es) | ||
| IN2013MU01154A (es) | ||
| IN2013MU01244A (es) | ||
| IN2013MU01250A (es) |